Terms: = Gastric cancer AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR AND Clinical Outcome
3 results:
1. Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric cancer.
Won E; Basunia A; Chatila WK; Hechtman JF; Chou JF; Ku GY; Chalasani SB; Boyar MS; Goldberg Z; Desai AM; Tuvy Y; Berger MF; Tang L; Kelsen DP; Schattner M; Ilson DH; Capanu M; Solit DB; Schultz N; Janjigian YY
Clin Cancer Res; 2019 Jul; 25(13):3811-3817. PubMed ID: 30952642
[TBL] [Abstract] [Full Text] [Related]
2. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with fgfr2 polysomy or gene amplification.
Van Cutsem E; Bang YJ; Mansoor W; Petty RD; Chao Y; Cunningham D; Ferry DR; Smith NR; Frewer P; Ratnayake J; Stockman PK; Kilgour E; Landers D
Ann Oncol; 2017 Jun; 28(6):1316-1324. PubMed ID: 29177434
[TBL] [Abstract] [Full Text] [Related]
3. Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy.
Kim HK; Choi IJ; Kim CG; Kim HS; Oshima A; Yamada Y; Arao T; Nishio K; Michalowski A; Green JE
Pharmacogenomics J; 2012 Apr; 12(2):119-27. PubMed ID: 21173787
[TBL] [Abstract] [Full Text] [Related]
